The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Breast Cancer Case Studies

Case Studies: Adjuvant Dual HER2-Targeted Therapy for HER2+ Early-Stage Breast Cancer

In this case-based interview, Ruth O’Regan, MD, reviews a 49-year-old female patient with HER2+ early-stage breast cancer and provides the options for therapy including adjuvant therapy.

Adjuvant Dual HER2-Targeted Therapy for HER2+ Early-Stage Breast Cancer

  • A 49-year-old women was referred for biopsy after routine mammography showed a 2.4-cm diameter spiculated mass in the left breast
  • PE: revealed a well-circumscribed, non-tender firm mass in the lower-outer quadrant of the left breast; singular palpable nodal enlargement in the left axilla
  • Excisional biopsy of the breast and axillary lymph nodes showed high grade lobular carcinoma
    • ER-/PR-; HER2 IHC 3+; Ki-67, 89%
    • Staging, pT2N3M0
  • She underwent right mastectomy and lymph node dissection
  • The patient was started on adjuvant chemotherapy with docetaxel + carboplatin with 12 months of trastuzumab + pertuzumab
Publications
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.